Journal of Clinical Oncology, Vol 15, 2807-2817, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

NK Cheung, G Heller, BH Kushner, C Liu and IY Cheung
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. cheungn@mskcc.org

PURPOSE: To measure the sensitivity of histologic examination in detecting metastatic solid tumor in bone marrow. PATIENTS AND METHODS: A total of 145 patients with stage 4 neuroblastoma underwent 840 marrow examinations, each consisting of six sites (four aspirates and two biopsies), from October 1990 to June 1996 at Memorial Sloan-Kettering Cancer Center. Metastasis was detected by either histology (aspirate by Wright-Giemse and biopsy by Hematoxylin-Eosin stains) or immunostaining of aspirates using anti-G(D2) monoclonal antibodies. RESULTS: The absence of tumor by histology at a single marrow site was a poor guarantee of the absence of disease. The number of false-negative sites increased as the percent of G(D2)-positive tumor cells in the marrow decreased: zero of six if tumor cell count was > or = 1%, and approximately six of six sites if < or = 0.003%. Sensitivity was comparable between marrow aspirate and biopsy. A lower bound (LB) for the probability of false-negative histology was calculated from the (1) discordance among the six marrow samplings and (2) comparison with immunofluorescence. When disease was extensive (eg, at diagnosis), the LB was 0.13 and 0.3, respectively. After treatment, it increased to 0.37 and 0.8. Examining multiple marrow sites can decrease the LB to 0.15. However, at least three sites have to be negative at relapse, six at diagnosis, and more than 50 during treatment or off-therapy follow- up. The marginal decrease in the LB by additional samplings rapidly diminished to less than 0.05 after two sites. CONCLUSION: Except at diagnosis and relapse when gross disease is present, marrow sampling by histology has limited sensitivity. Current practice grossly underestimates the true prevalence of marrow disease.

This article has been cited by other articles:

				C. Krishnan, C. J. Twist, T. Fu, and D. A. Arber Detection of Isolated Tumor Cells in Neuroblastoma by Immunohistochemical Analysis in Bone Marrow Biopsy Specimens: Improved Detection With Use of {beta}-Catenin Am J Clin Pathol, January 1, 2009; 131(1): 49 - 57. [Abstract] [Full Text] [PDF]

				J. Stutterheim, A. Gerritsen, L. Zappeij-Kannegieter, I. Kleijn, R. Dee, L. Hooft, M. M. van Noesel, M. Bierings, F. Berthold, R. Versteeg, et al. PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma J. Clin. Oncol., November 20, 2008; 26(33): 5443 - 5449. [Abstract] [Full Text] [PDF]

				K. Swerts, B. De Moerloose, C. Dhooge, J. Vandesompele, C. Hoyoux, K. Beiske, Y. Benoit, G. Laureys, and J. Philippe Potential Application of ELAVL4 Real-Time Quantitative Reverse Transcription-PCR for Detection of Disseminated Neuroblastoma Cells Clin. Chem., March 1, 2006; 52(3): 438 - 445. [Abstract] [Full Text] [PDF]

				K. Swerts, P. F. Ambros, C. Brouzes, J. M. F. Navarro, N. Gross, D. Rampling, R. Schumacher-Kuckelkorn, A. R. Sementa, R. Ladenstein, and K. Beiske Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow J. Histochem. Cytochem., December 1, 2005; 53(12): 1433 - 1440. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, M. S. Lo Piccolo, B. H. Kushner, and N.-K. V. Cheung Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma J. Clin. Oncol., October 15, 2003; 21(20): 3853 - 3858. [Abstract] [Full Text] [PDF]

				G. Mehes, A. Luegmayr, R. Kornmuller, I. M. Ambros, R. Ladenstein, H. Gadner, and P. F. Ambros Detection of Disseminated Tumor Cells in Neuroblastoma: 3 Log Improvement in Sensitivity by Automatic Immunofluorescence plus FISH (AIPF) Analysis Compared with Classical Bone Marrow Cytology Am. J. Pathol., August 1, 2003; 163(2): 393 - 399. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, M. S. Lo Piccolo, B. H. Kushner, K. Kramer, and N.-K. V. Cheung Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma J. Clin. Oncol., March 15, 2003; 21(6): 1087 - 1093. [Abstract] [Full Text] [PDF]

				B. H. Kushner, H. W.D. Yeung, S. M. Larson, K. Kramer, and N.-K. V. Cheung Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients J. Clin. Oncol., July 15, 2001; 19(14): 3397 - 3405. [Abstract] [Full Text] [PDF]

				M. M. Meck, M. Wierdl, L. M. Wagner, R. A. Burger, S. M. Guichard, Erik. J. Krull, L. C. Harris, P. M. Potter, and M. K. Danks A Virus-directed Enzyme Prodrug Therapy Approach to Purging Neuroblastoma Cells from Hematopoietic Cells Using Adenovirus Encoding Rabbit Carboxylesterase and CPT-11 Cancer Res., July 1, 2001; 61(13): 5083 - 5089. [Abstract] [Full Text] [PDF]

				I. Y. Cheung and N.-K. V. Cheung Quantitation of Marrow Disease in Neuroblastoma by Real-Time Reverse Transcription-PCR Clin. Cancer Res., June 1, 2001; 7(6): 1698 - 1705. [Abstract] [Full Text] [PDF]

				R. C. Seeger, C. P. Reynolds, R. Gallego, D. O. Stram, R. B. Gerbing, and K. K. Matthay Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children's Cancer Group Study J. Clin. Oncol., December 15, 2000; 18(24): 4067 - 4076. [Abstract] [Full Text] [PDF]

				L. B. Faulkner, A. Garaventa, A. Paoli, V. Tintori, A. Tamburini, L. Lacitignola, M. Veltroni, M. S. L. Piccolo, E. Viscardi, C. Milanaccio, et al. In Vivo Cytoreduction Studies and Cell Sorting-Enhanced Tumor-Cell Detection in High-Risk Neuroblastoma Patients: Implications for Leukapheresis Strategies J. Clin. Oncol., November 15, 2000; 18(22): 3829 - 3836. [Abstract] [Full Text] [PDF]

				J. Mora, N.-K. V. Cheung, B. H. Kushner, M. P. LaQuaglia, K. Kramer, M. Fazzari, G. Heller, L. Chen, and W. L. Gerald Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p J. Mol. Diagn., February 1, 2000; 2(1): 37 - 46. [Abstract] [Full Text]

				B. H. Kushner, K. Kramer, and N.-K. V. Cheung Oral Etoposide for Refractory and Relapsed Neuroblastoma J. Clin. Oncol., October 1, 1999; 17(10): 3221 - 3225. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, N.-K. V. Cheung, R. A. Ghossein, J. M. Satagopan, S. Bhattacharya, and D. G. Coit Association between Molecular Detection of GAGE and Survival in Patients with Malignant Melanoma: A Retrospective Cohort Study Clin. Cancer Res., August 1, 1999; 5(8): 2042 - 2047. [Abstract] [Full Text] [PDF]